Radiation-induced dimer formation of EGFR: Implications for the radiosensitizing effect of cetuximab

Anticancer Research

Volumn 33, Issue 10, 2013, Pages 4337-4346

  Kiyozuka, Makoto ^a   Akimoto, Tetsuo ^a,b   Fukutome, Mika ^a   Motegi, Atsushi ^a,b   Mitsuhashi, Norio ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

A431 cells; Cetuximab; Dimerization; EGFR; Radiation; Radiosensitivity

Indexed keywords

3,3' DITHIOBIS(SUCCINIMIDYL PROPIONATE); CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; RAF PROTEIN;

ARTICLE; AUTOPHOSPHORYLATION; CARCINOMA CELL; CONTROLLED STUDY; CROSS LINKING; DIMERIZATION; DRUG EFFECT; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IRRADIATION; PRIORITY JOURNAL; RADIATION; RADIATION EQUIPMENT; RADIOSENSITIVITY; SQUAMOUS CELL CARCINOMA; VULVA CARCINOMA; WESTERN BLOTTING;

A431 CELLS; CETUXIMAB; DIMERIZATION; EGFR; RADIATION; RADIOSENSITIVITY;

ANTIBODIES, MONOCLONAL, HUMANIZED; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; PHOSPHORYLATION; PROTEIN MULTIMERIZATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; RADIATION-SENSITIZING AGENTS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 84891356953     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Brown JM: Therapeutic targets of radiotherapy Int J Radiat Oncol Biol Phys 49: 319-326, 2001.
2. Harari PM and Huang SM: Radiation response modification following molecular inhibition of epidermal growth factor receptor signaling Semin Radiat Oncol 11: 281-289, 2001.
3. Dent P, Reardon DB, Park JS, Bowers G, Logsdon C, Valerie K and Schmidt-Ullrich R: Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. Mol Biol Cell 10: 2493-2506, 1999.
4. Contessa JN, Hampton J and Lammering G: Ionizing radiation activates Erb-B receptor dependent Akt and p70 S6 kinase signaling in carcinoma cells. Oncogene 21: 4032-4041, 2002.
5. Hagan M, Wang L and Hanley JR: Ionizing radiation-induced mitogen-activated protein (MAP) kinase activation in DU145 prostate carcinoma cells: MAP kinase inhibition enhances radiation-induced cell killing and G2/M-phase arrest. Radiat Res 153: 371-383, 2000.
6. Dent P, Yacoub A and Fisher PB: MAPK pathways in radiation responses Oncogene 22: 5885-5896, 2003.
7. Akimoto T, Hunter NR and Buchmiller L: Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res 5: 2884-2890, 1999
8. Huang SM, Bock JM and Harari PM: Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 59: 1935-1940, 1999
9. Milas L, Mason K and Hunter N: In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 6: 701-708, 2000.
10. Schmidt-Ullrich RK, Mikkelsen RB and Dent P: Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene 15: 1191-1197, 1997.
11. Schlessinger J: Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell 110: 669-672, 2002.
12. Burgess AW, Cho HS and Eigenbrot C: An open-and-shut case? Recent insights into the activation of EGF/ERBB receptors. Mol Cell 12: 541-552, 2003.
13. Ang KK, Berkey BA and Tu X: Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62: 7350-7356, 2002.
14. Akimoto T, Nonaka T and Harashima K: Selective inhibition of survival signal transduction pathways enhanced radiosensitivity in human esophageal cancer cell lines in vitro. Anticancer Res 24(2B): 811-819, 2004.
15. Akimoto T, Nonaka T and Ishikawa H: Genistein, a tyrosine kinase inhibitor, enhanced radiosensitivity in human esophageal cancer cell lines in vitro: Possible involvement of inhibition of survival signal transduction pathways. Int J Radiat Oncol Biol Phys 50: 195-201, 2001.
16. Huang SM, Bock JM and Harari PM: Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 59: 1935-1940, 1999.
17. Liang K, Ang KK and Milas L: The epidermal growth factor receptor mediates radioresistance. Int J Radiat Oncol Biol Phys 57: 246-254, 2003.
18. Bonner JA, Buchsbaum DJ and Rogers BE: Adenoviral vector-mediated augmentation of epidermal growth factor receptor (EGFr) enhances the radiosensitization properties of anti-EGFr treatment in prostate cancer cells. Int J Radiat Oncol Biol Phys 58: 950-958, 2004.
19. Bonner JA, Buchsbaum DJ and Russo SM: Anti-EGFR-mediated radiosensitization as a result of augmented EGFR expression. Int J Radiat Oncol Biol Phys 59(2 Suppl): 2-10, 2004.
20. Liu P, Sudhaharan T and Koh RM: Investigation of the dimerization of proteins from the epidermal growth factor receptor family by single wavelength fluorescence cross-correlation spectroscopy. Biophys J 93: 684-698, 2007.
21. Ye D, Mendelsohn J and Fan Z: Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human mouse chimeric anti-EGF receptor mAb C225. Oncogene 18: 731-738, 1999.
22. Worthylake R, Opresko LK and Wiley HS: ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. J Biol Chem 274: 8865-8874, 1999.
23. Fukutome M, Maebayashi K and Nasu S: Enhancement of radiosensitivity by dual inhibition of the HER family with ZD1839 (Iressa) and trastuzumab (Herceptin). Int J Radiat Oncol Biol Phys 66: 528-536, 2006.
24. Ferguson KM: Active and inactive conformations of the epidermal growth factor receptor. Biochem Soc Trans 32(Pt 5): 742-745, 2004.
25. Johns TG, Stockert E and Ritter G: Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene. Int J Cancer 98: 398-408, 2002.
26. Ferguson KM: Active and inactive conformations of the epidermal growth factor receptor. Biochem Soc Trans 32(Pt 5): 742-745, 2004.
27. Schmitz KR and Ferguson KM: Interaction of antibodies with ErbB receptor extracellular regions. Exp Cell Res 315: 659-670, 2009.
28. Li S, Schmitz KR and Jeffrey PD: Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 7: 301-311, 2005.
29. Johns TG, Mellman I and Cartwright GA: The antitumor monoclonal antibody 806 recognizes a high-mannose form of the EGF receptor that reaches the cell surface when cells overexpress the receptor. FASEB J 19: 780-782, 2005.
30. Tao RH and Maruyama IN: All EGF (ErbB) receptors have preformed homo- and heterodimeric structures in living cells. J Cell Sci 121(Pt 19): 3207-3217, 2008.
31. Ogiso H, Ishitani R and Nureki O: Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 110: 775-787, 2002.
32. Garrett TP, McKern NM and Lou M: The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol Cell 11: 495-505, 2003.
33. Kumagai T, Katsumata M and Hasegawa A: Role of extracellular subdomains of p185c-neu and the epidermal growth factor receptor in ligand-independent association and transactivation. Proc Natl Acad Sci USA 100: 9220-9225, 2003.